More aggressive treatment warranted in patients with metabolic syndrome
Early online publication: Tuesday, September 5, 2006
More aggressive treatment with statins is necessary to lower LDL (low-density lipoprotein) cholesterol in patients with coronary heart disease and metabolic syndrome, a syndrome composing of three cardiovascular risk factors (see Editor's Notes) according to an Article published online today (Tuesday September 5, 2006) by The Lancet.
The Treating to New Targets (TNT) study was a prospective, double blind, parallel-group trial which was done at 256 sites in 14 countries between 1998 and 2004, with a median follow-up of 4.9 years. The analysis by Prakash Deedwania and colleagues (University of California, San Francisco, USA) involved 5584 patients with metabolic syndrome and clinically evident coronary heart disease aged 35--75 years.
The patients were randomly assigned to receive either atorvastatin 10mg per day or 80mg per day (aggressive treatment). At 3 months patients on 10mg per day had mean LDL cholesterol concentrations of 2.5mmol/L, compared with 1.9mmol/L in the aggressively treated patients. Major cardiovascular events occurred in 13% patients receiving atorvastatin 10mg, compared with 9.5% receiving 80mg. Irrespective of treatment, significantly more patients with metabolic syndrome (11.3%) had a major cardiovascular event than those without metabolic syndrome (8%). This increased risk was significantly reduced by intensive therapy with atorvastatin 80mg beyond that achieved with 10mg. The analysis suggests that the risk of major cardiovascular events increases with the presence of each component of the metabolic syndrome, and patients with diabetes also have a much higher risk.
By focusing aggressive statins therapy (80mg a day instead of 10mg a day) on patients with metabolic syndrome or diabetes in a population with stable coronary heart disease, allows the number needed to treat to be reduced significantly, which gains a significant improvement in the cost-effectiveness of high statin dose.
Notes to Editors: Metabolic Syndrome--Although there is some disagreement about the criteria for metabolic syndrome, it is generally described as the clustering of at least three cardiovascular risk factors, such as insulin resistance, obesity, large waist circumference, hypertension, and dyslipidiaemia*. The metabolic syndrome has been closely linked to diabetes and cardiovascular disease.
*Dislipidaemia--A disorder of lipoprotein metabolism, including lipoprotein overproduction or deficiency. Dyslipidaemia may be manifested by elevation of the total cholesterol, LDL cholesterol and the triglyceride concentrations, and a decrease in the "good" high-density lipoprotein (HDL) cholesterol concentration in the blood.
Professor Prakash C Deedwania, Professor of Medicine, University of California, San Francisco, VA Central California Healthcare System, 2615 E Clinton Avenue, Fresno CA 93703, USA. T) +93-4414177 (Hotel Milleni Apsis, Barcelona. From September 2 to 7) email@example.com
Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.